Disease progression and liver cancer in the ferroportin disease
Abstract
We have had the opportunity to study six members of a pedigree carrying the A77D mutation of FPN for 11–24 years in whom the disease was first described.1,2Keywords
This publication has 10 references indexed in Scilit:
- Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implicationsNature Clinical Practice Gastroenterology & Hepatology, 2004
- The ferroportin diseaseBlood Cells, Molecules, and Diseases, 2004
- Autosomal dominant reticuloendothelial iron overload associated with a 3–base pair deletion in the ferroportin 1 gene(SLC11A3)Blood, 2002
- Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) geneJournal of Clinical Investigation, 2001
- Autosomal-dominant hemochrom-atosis is associated with a mutation in the ferroportin (SLC11A3) geneJournal of Clinical Investigation, 2001
- Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: Oxyradical overload diseasesProceedings of the National Academy of Sciences, 2000
- Hereditary Hemochromatosis in Adults without Pathogenic Mutations in the Hemochromatosis GeneNew England Journal of Medicine, 1999
- The Role of Kupffer Cells in the Surveillance of Tumor Growth in the LiverJournal of Surgical Research, 1993
- p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells.1993
- KUPFFER-CELL DEPLETION IN CHRONIC LIVER DISEASE: IMPLICATIONS FOR HEPATIC CARCINOGENESISThe Lancet, 1983